JP2019526262A5 - - Google Patents

Download PDF

Info

Publication number
JP2019526262A5
JP2019526262A5 JP2019512264A JP2019512264A JP2019526262A5 JP 2019526262 A5 JP2019526262 A5 JP 2019526262A5 JP 2019512264 A JP2019512264 A JP 2019512264A JP 2019512264 A JP2019512264 A JP 2019512264A JP 2019526262 A5 JP2019526262 A5 JP 2019526262A5
Authority
JP
Japan
Prior art keywords
gene
recombinant
lab
pharmaceutical composition
nucleic acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2019512264A
Other languages
English (en)
Japanese (ja)
Other versions
JP2019526262A (ja
JP7016865B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/IB2017/055287 external-priority patent/WO2018042390A1/en
Publication of JP2019526262A publication Critical patent/JP2019526262A/ja
Publication of JP2019526262A5 publication Critical patent/JP2019526262A5/ja
Priority to JP2022010063A priority Critical patent/JP2022061035A/ja
Application granted granted Critical
Publication of JP7016865B2 publication Critical patent/JP7016865B2/ja
Priority to JP2024009123A priority patent/JP2024047590A/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2019512264A 2016-09-02 2017-09-02 Il-10およびインスリンを安定的に発現する遺伝子改変された細菌 Expired - Fee Related JP7016865B2 (ja)

Priority Applications (2)

Application Number Priority Date Filing Date Title
JP2022010063A JP2022061035A (ja) 2016-09-02 2022-01-26 Il-10およびインスリンを安定的に発現する遺伝子改変された細菌
JP2024009123A JP2024047590A (ja) 2016-09-02 2024-01-25 Il-10およびインスリンを安定的に発現する遺伝子改変された細菌

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662383079P 2016-09-02 2016-09-02
US62/383,079 2016-09-02
PCT/IB2017/055287 WO2018042390A1 (en) 2016-09-02 2017-09-02 Genetically modified bacteria stably expressing il-10 and insulin

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2022010063A Division JP2022061035A (ja) 2016-09-02 2022-01-26 Il-10およびインスリンを安定的に発現する遺伝子改変された細菌

Publications (3)

Publication Number Publication Date
JP2019526262A JP2019526262A (ja) 2019-09-19
JP2019526262A5 true JP2019526262A5 (https=) 2020-10-15
JP7016865B2 JP7016865B2 (ja) 2022-03-03

Family

ID=60120085

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2019512264A Expired - Fee Related JP7016865B2 (ja) 2016-09-02 2017-09-02 Il-10およびインスリンを安定的に発現する遺伝子改変された細菌
JP2022010063A Pending JP2022061035A (ja) 2016-09-02 2022-01-26 Il-10およびインスリンを安定的に発現する遺伝子改変された細菌
JP2024009123A Pending JP2024047590A (ja) 2016-09-02 2024-01-25 Il-10およびインスリンを安定的に発現する遺伝子改変された細菌

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2022010063A Pending JP2022061035A (ja) 2016-09-02 2022-01-26 Il-10およびインスリンを安定的に発現する遺伝子改変された細菌
JP2024009123A Pending JP2024047590A (ja) 2016-09-02 2024-01-25 Il-10およびインスリンを安定的に発現する遺伝子改変された細菌

Country Status (8)

Country Link
US (3) US10858663B2 (https=)
EP (1) EP3506932B1 (https=)
JP (3) JP7016865B2 (https=)
CN (2) CN109843320A (https=)
AU (1) AU2017319707B2 (https=)
CA (1) CA3035151A1 (https=)
RU (1) RU2768027C2 (https=)
WO (1) WO2018042390A1 (https=)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7016865B2 (ja) * 2016-09-02 2022-03-03 イントレクソン・アクトバイオテイクス・エヌブイ Il-10およびインスリンを安定的に発現する遺伝子改変された細菌
CN109983028B (zh) 2016-09-13 2023-10-20 英特瑞克斯顿阿克图比奥帝克斯有限公司 黏膜黏附性微生物
EP4582440A3 (en) * 2018-12-21 2025-10-08 The Regents of the University of California Il-10-containing vaccines and uses thereof
IL322315A (en) 2019-05-14 2025-09-01 Provention Bio Inc Methods and preparations for preventing type 1 diabetes
AU2021287998B2 (en) 2020-06-11 2026-03-12 Benaroya Research Institute At Virginia Mason Methods and compositions for preventing type 1 diabetes
US12565529B2 (en) 2021-05-24 2026-03-03 Provention Bio, Inc. Methods for treating type 1 diabetes
WO2024146463A1 (zh) * 2023-01-03 2024-07-11 深圳先进技术研究院 分泌白介素-10的细菌
CN116726158A (zh) * 2023-04-24 2023-09-12 中国医学科学院医学生物学研究所 一种多表位1型糖尿病疫苗及其制备方法

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB227835A (en) 1924-01-15 1925-04-09 Harry Odell Improvements in feeding mechanism for embossing and other printing presses
US4919918A (en) 1988-03-14 1990-04-24 Spectrum Consumer Products Co., Inc. Non-alcoholic mouthwash
US5972685A (en) 1988-07-21 1999-10-26 Iowa State University Research Foundation, Inc. Oral administration of coprostanol producing microorganisms to humans to decrease plasma cholesterol concentration
GB9126306D0 (en) 1991-12-11 1992-02-12 Unilever Plc Mouthwash compositions
JPH07504815A (ja) 1992-02-27 1995-06-01 マイクロバイアル テクニクス リミティド 乳酸菌における異種遺伝子の発現およびその発現産物
US5223285A (en) 1992-03-31 1993-06-29 Abbott Laboratories Nutritional product for pulmonary patients
US5700782A (en) 1993-05-28 1997-12-23 Abbott Laboratories Enteral nutritional product
WO1996032486A1 (en) 1995-04-11 1996-10-17 Nederlandse Organisatie Voor Toegepast-Natuurwetenschappelijk Onderzoek Tno Method for the construction of vectors for lactic acid bacteria like lactobacillus such that the bacteria can efficiently express, secrete and display proteins at the surface
US5695746A (en) 1995-07-28 1997-12-09 Chesebrough-Pond's Usa Co., Division Of Conopco, Inc. Liquid dentifrice with mouthwash fresh taste
WO1997026855A1 (en) 1996-01-24 1997-07-31 Warner-Lambert Company Peroxide/essential oils containing mouthwash compositions and two-part mouthwash systems
GB9611364D0 (en) 1996-05-31 1996-08-07 Smithkline Beecham Plc Composition
PT939613E (pt) 1996-09-18 2003-07-31 Erling Johansen Solucao sobressaturada para lavagem bucal contendo ioes calcio e fosfato
US5869118A (en) 1996-11-13 1999-02-09 Abbott Laboratories Gellan gum to improve physical stability of liquid nutritional products
US5897872A (en) 1997-11-12 1999-04-27 Picciano; Dante J. Iodine-containing nasal moisturizing saline solution
US6171611B1 (en) 1997-11-12 2001-01-09 Dante J. Picciano Iodine-containing nasal moisturizing saline and mouthwash solutions
JP5068401B2 (ja) 1998-09-28 2012-11-07 カプスゲル・ベルギウム・ナムローゼ・フェンノートシャップ Hpmcカプセルを使用する腸及び結腸への送達
AU1071200A (en) 1998-10-19 2000-05-08 Biotech Australia Pty Limited Systems for oral delivery
WO2002090551A2 (en) 2001-05-03 2002-11-14 Vlaams Interuniversitair Instituut Voor Biotechnologie Vzw Self-containing lactococcus strain
US20040043003A1 (en) * 2002-01-31 2004-03-04 Wei Chen Clinical grade vectors based on natural microflora for use in delivering therapeutic compositions
US20040076590A1 (en) 2002-07-08 2004-04-22 Wilkins Joe S. Antibacterial toothpaste and mouthwash formulations
WO2004056850A2 (en) * 2002-12-19 2004-07-08 Vib Vzw Mutant proteins showing increased secretion
AU2006319216B2 (en) 2005-11-29 2012-09-13 Intrexon Actobiotics Nv Induction of mucosal tolerance to antigens
EP2115146B1 (en) 2007-01-12 2016-07-06 Intrexon Actobiotics NV Lactococcus promoters and uses thereof
CN103933563B (zh) 2007-01-25 2016-09-28 英特瑞克斯顿阿克图比奥帝克斯有限公司 使用遗传修饰的乳杆菌通过抗原的粘膜递送治疗免疫疾病
BRPI0809448A2 (pt) * 2007-03-28 2014-09-09 Alimentary Health Ltd Cepas de bifidobacterium probióticas
JP5572972B2 (ja) * 2009-03-16 2014-08-20 Jnc株式会社 インスリン分泌促進剤などの薬物のスクリーニング方法
WO2010124855A1 (en) 2009-04-30 2010-11-04 Actogenix Nv Cryoprotectants for freeze drying of lactic acid bacteria
WO2012164083A1 (en) * 2011-06-01 2012-12-06 Actogenix N.V. Polycistronic expression system for bacteria
EP3382006B1 (en) * 2011-09-23 2021-02-17 Intrexon Actobiotics NV Modified gram positive bacteria and uses thereof
WO2013041672A1 (en) * 2011-09-23 2013-03-28 Actogenix Nv Modified gram positive bacteria and uses thereof
JP7016865B2 (ja) * 2016-09-02 2022-03-03 イントレクソン・アクトバイオテイクス・エヌブイ Il-10およびインスリンを安定的に発現する遺伝子改変された細菌

Similar Documents

Publication Publication Date Title
JP2019526262A5 (https=)
Ma et al. Oral administration of recombinant Lactococcus lactis expressing HSP65 and tandemly repeated P277 reduces the incidence of type I diabetes in non-obese diabetic mice
AU2017208153B2 (en) Compositions and methods for the treatment of type 1 diabetes
Rutella et al. Intestinal dendritic cells in the pathogenesis of inflammatory bowel disease
US20230348918A1 (en) Genetically Modified Bacteria Stably Expressing IL-10 and Insulin
Huss et al. TGF‐β signaling via Smad4 drives IL‐10 production in effector Th1 cells and reduces T‐cell trafficking in EAE
KR101291960B1 (ko) 장내세균에 의한 생물학적 활성제의 제어된 생산 및 전달
US20080026986A1 (en) Reversal of the suppressive function of specific t cells via toll-like receptor 8 signaling
WO2013158553A1 (en) Multivalent breast cancer vaccine
CN113056479A (zh) 腺病毒疫苗媒介物中的cd40和cd40l结合物
EP4041758A1 (en) An oncolytic virus vector coding for variant interleukin-2 (vil-2) polypeptide
Torres et al. IL-12p40/IL-10 producing preCD8α/Clec9A+ dendritic cells are induced in neonates upon Listeria monocytogenes infection
Salio Unconventional MAIT cell responses to bacterial infections
Cannon et al. Cellular immunotherapy for ovarian cancer
Roider et al. Invasion and destruction of a murine fibrosarcoma by Salmonella-induced effector CD8 T cells as a therapeutic intervention against cancer
WO2022086988A1 (en) Multi-functional and multi-valent interleukin-tgf-beta receptor fusion polypeptides
EP4232466A1 (en) Multi-functional and multi-valent interleukin-tgf-beta receptor fusion polypeptides
CN114761028A (zh) 乳糜泻的治疗
Kong et al. Expression of fusion IL2-B7. 1 (IgV+ C) and effects on T lymphocytes
WO2024216073A1 (en) Engineered microbes comprising tumor neoantigen vectors for cancer immunotherapy
CN120476198A (zh) 分泌白介素-10的细菌
Memory Differential Requirements for OX40 Signals